# ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

> **NCT03595917** · PHASE1 · RECRUITING · sponsor: **Marlise Luskin, MD** · enrollment: 40 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

## Interventions

- **DRUG:** ABL001
- **DRUG:** Dasatinib
- **DRUG:** Prednisone
- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT03595917
- **Lead sponsor:** Marlise Luskin, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-07-24
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595917, "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03595917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*